Overview

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
0
Participant gender:
All
Summary
This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xiangya Hospital of Central South University
Treatments:
Exenatide
Liraglutide
Criteria
Inclusion Criteria:

1. Patients aged 18 to 65 years (to the date of screening)；

2. The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity
(male waist circumference is greater than 90cm, female waist is greater than 85cm).

3. Nearly a month have not used weight-related drugs,including various weight-loss
drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid
drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1
month,and the drug dose remained constant or decreased during the trial.

4. Weight stable for more than 3 months (weight fluctuations <5%).

Exclusion Criteria:

1. pregnant female.

2. Secondary diseases caused by other diseases: including hypothyroidism, increased
cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of
drug-induced obesity, and others.

3. Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial
infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or
pulmonary insufficiency, renal failure, severe hepatitis.

4. Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis,
hyperosmolar state of diabetes.

5. Nearly a month had surgery, trauma, infection and so on.

6. Limb deformity incomplete, difficult to accurately determine the height, weight and
other physical indicators.

7. Poor medication compliance or serious side effects (severe rash, syncope, etc.).